News coverage about Endocyte (NASDAQ:ECYT) has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Endocyte earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 44.7380447212439 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Several equities analysts have recently issued reports on the company. Cowen reaffirmed a “hold” rating on shares of Endocyte in a research note on Monday, October 2nd. ValuEngine raised Endocyte from a “strong sell” rating to a “sell” rating in a research note on Monday, October 2nd. Zacks Investment Research raised Endocyte from a “sell” rating to a “hold” rating in a research note on Thursday, November 9th. Finally, Wedbush raised Endocyte from a “neutral” rating to an “outperform” rating and upped their price target for the company from $2.00 to $7.00 in a research note on Tuesday, October 3rd.
Shares of Endocyte (NASDAQ:ECYT) traded up $0.02 on Friday, hitting $4.06. The stock had a trading volume of 397,519 shares, compared to its average volume of 531,604. Endocyte has a twelve month low of $1.17 and a twelve month high of $6.55. The firm has a market capitalization of $172.86, a price-to-earnings ratio of -3.01 and a beta of 2.20.
Endocyte (NASDAQ:ECYT) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.20). Endocyte had a negative net margin of 82,235.72% and a negative return on equity of 38.91%. The firm had revenue of $0.03 million for the quarter. During the same quarter in the previous year, the business earned ($0.21) earnings per share. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. sell-side analysts expect that Endocyte will post -1.24 EPS for the current fiscal year.
In other Endocyte news, VP Christopher P. Leamon sold 23,231 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $5.04, for a total value of $117,084.24. Following the transaction, the vice president now owns 150,579 shares of the company’s stock, valued at $758,918.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Philip S. Low bought 5,600 shares of the business’s stock in a transaction on Monday, November 13th. The stock was bought at an average cost of $4.84 per share, for a total transaction of $27,104.00. Following the purchase, the insider now directly owns 283,005 shares of the company’s stock, valued at approximately $1,369,744.20. The disclosure for this purchase can be found here. Insiders have sold 124,253 shares of company stock worth $562,591 in the last ninety days. 14.86% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: This report was published by Stock Observer and is the property of of Stock Observer. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.thestockobserver.com/2018/01/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-endocyte-ecyt-stock-price.html.
Endocyte Company Profile
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.